A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...

Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related ...

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...

H.C. Wainwright adjusted its outlook on Cullinan Oncology Inc. (NASDAQ:CGEM), raising the price target to $33.00 from the previous $28.00 while maintaining a Buy rating on the company's shares.

Zipalertinib是一款靶向EGFR激活性突变体的口服小分子抑制剂。它能够抑制携带外显子20插入突变的EGFR变体，同时避免对野生型EGFR的抑制。Zipalertinib旨在作为下一代不可逆EGFR抑制剂，用于治疗特定基因亚型的NSCLC患者。它已获得FDA授予的突破性疗法认定。

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. have announced the successful outcome ...

JonesTrading analyst Soumit Roy maintained a Buy rating on Cullinan Management (CGEM – Research Report) today and set a price target of ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...